Lys117

Site Information
FDDDDSGkISLRNLR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12246104

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 , 7 )
Relevant cell line - cell type - tissue:	HEK293T (epithelial) ( 5 ) , HEp-2 (squamous) ( 1 ) , Jurkat (T lymphocyte) ( 1 , 3 ) , LNCaP (prostate cell) ( 6 , 7 ) , MV4-11 (macrophage) ( 5 ) , U2OS (bone cell) ( 4 )

Upstream Regulation
Treatments:	MG132 ( 5 )

References
1	Akimov V, et al. (2018) UbiSite approach for comprehensive mapping of lysine and N-terminal ubiquitination sites. Nat Struct Mol Biol 25, 631-640 29967540 Curated Info
2	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
3	Udeshi ND, et al. (2013) Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics 12, 825-31 23266961 Curated Info
4	Povlsen LK, et al. (2012) Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol 14, 1089-98 23000965 Curated Info
5	Wagner SA, et al. (2011) A Proteome-wide, Quantitative Survey of In Vivo Ubiquitylation Sites Reveals Widespread Regulatory Roles. Mol Cell Proteomics 10, M111.013284 21890473 Curated Info
6	Possemato A (2009) CST Curation Set: 8242; Year: 2010; Biosample/Treatment: cell line, LNCaP/AAG; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info
7	Possemato A (2009) CST Curation Set: 8241; Year: 2010; Biosample/Treatment: cell line, LNCaP/control; Disease: prostate cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: Ub(K-e-GG) Curated Info